Avanir Pharmaceuticals (AVNR) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AVNR Hot Sheet
Price: $16.96 --0%
Financial Fact:
Net product sales: 26.54M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Net product sales: 26.54M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $26.9 million versus the consensus estimate of $28.21 million.
For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Chilean Cobalt signs $28.3M option for La Cobaltera mining land
- Wolfe Research Reiterates Outperform Rating on AMD (AMD)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
